Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 16Sarcoma 3Genitourinary 3Gynecologic 2Thoracic 1Lymphoid 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Sarcoma 1Hemangiosarcoma 1Gliosarcoma 1Glioblastoma 1

Interventions

Cyclophosphamide 93Doxorubicin 92Radiotherapy 87Temozolomide 69Filgrastim 58Ifosfamide 55Bevacizumab 55Etoposide 48Gemcitabine 44Imatinib Mesylate 43Vincristine 40pembrolizumab 35pazopanib 34Peripheral Blood Stem Cell Transplantation 31Methotrexate 31Nivolumab 30Carboplatin 30fludarabine phosphate 29Irinotecan 29Cisplatin 28Paclitaxel 26Melphalan 26Magnetic Resonance Spectroscopy 26Docetaxel 25Busulfan 25Trabectedin 24apatinib 22Specimen Handling 21Sirolimus 21Antilymphocyte Serum 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × balstilimab × Sarcoma × Clear all
NCT05864534 2026-05-13

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Northwestern University

Phase 2 Recruiting
25 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT04028063 2026-04-20

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

University of Colorado, Denver

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Sarcoma

NCT04607200 2022-01-11

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Agenus Inc.

Phase 2 Withdrawn
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡